Մոնոկլոնալ հակամարմինային թերապիա (Armenian Wikipedia)

Analysis of information sources in references of the Wikipedia article "Մոնոկլոնալ հակամարմինային թերապիա" in Armenian language version.

refsWebsite

Global rank Armenian rank

41nih.gov

4^th place

3^rd place

29doi.org

2^nd place

4^th place

6harvard.edu

18^th place

38^th place

5archive.org

6^th place

1zenodo.org

621^st place

1,041^st place

1worldcat.org

5^th place

10^th place

1radiopaedia.org

4,968^th place

1,981^st place

1landesbioscience.com

low place

archive.org

Baxter, David (December 2007). «Active and passive immunity, vaccine types, excipients and licensing». Occupational Medicine. 57 (8): 552–6. doi:10.1093/occmed/kqm110. PMID 18045976.
Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF (September 1980). «Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen». Cancer Research. 40 (9): 3147–54. PMID 7427932.
Rang, H. P. (2003). Pharmacology. Edinburgh: Churchill Livingstone. էջ 241. ISBN 978-0-443-07145-4.
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH (September 2002). «A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours». British Journal of Cancer. 87 (6): 600–7. doi:10.1038/sj.bjc.6600517. PMC 2364249. PMID 12237768.
Hooks MA, Wade CS, Millikan WJ (1991). «Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation». Pharmacotherapy. 11 (1): 26–37. doi:10.1002/j.1875-9114.1991.tb03595.x (inactive 2020 թ․ մայիսի 21). PMID 1902291.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2020 (link)

doi.org

Waldmann TA (March 2003). «Immunotherapy: past, present and future». Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576.
Sharma P, Allison JP (April 2015). «The future of immune checkpoint therapy». Science. 348 (6230): 56–61. Bibcode:2015Sci...348...56S. doi:10.1126/science.aaa8172. PMID 25838373.
Olinger GG, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L (October 2012). «Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques». Proceedings of the National Academy of Sciences of the United States of America. 109 (44): 18030–5. Bibcode:2012PNAS..10918030O. doi:10.1073/pnas.1213709109. PMC 3497800. PMID 23071322.
Baxter, David (December 2007). «Active and passive immunity, vaccine types, excipients and licensing». Occupational Medicine. 57 (8): 552–6. doi:10.1093/occmed/kqm110. PMID 18045976.
Modified from Carter P (November 2001). «Improving the efficacy of antibody-based cancer therapies». Nature Reviews. Cancer. 1 (2): 118–29. doi:10.1038/35101072. PMID 11905803.
Prof FC Breedveld (2000). «Therapeutic monoclonal antibodies». Lancet. 355 (9205): 735–740. doi:10.1016/S0140-6736(00)01034-5. PMID 10703815.
Köhler G, Milstein C (August 1975). «Continuous cultures of fused cells secreting antibody of predefined specificity». Nature. 256 (5517): 495–7. Bibcode:1975Natur.256..495K. doi:10.1038/256495a0. PMID 1172191.
Ritz J, Schlossman SF (January 1982). «Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma». Blood. 59 (1): 1–11. doi:10.1182/blood.V59.1.1.1. PMID 7032624.
Stern M, Herrmann R (April 2005). «Overview of monoclonal antibodies in cancer therapy: present and promise». Critical Reviews in Oncology/Hematology. 54 (1): 11–29. doi:10.1016/j.critrevonc.2004.10.011. PMID 15780905.
Hudson PJ, Souriau C (January 2003). «Engineered antibodies». Nature Medicine. 9 (1): 129–34. doi:10.1038/nm0103-129. PMID 12514726.
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (May 1992). «Humanization of an anti-p185HER2 antibody for human cancer therapy». Proceedings of the National Academy of Sciences of the United States of America. 89 (10): 4285–9. Bibcode:1992PNAS...89.4285C. doi:10.1073/pnas.89.10.4285. PMC 49066. PMID 1350088.
Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR (1989). «Conformations of immunoglobulin hypervariable regions». Nature. 342 (6252): 877–83. Bibcode:1989Natur.342..877C. doi:10.1038/342877a0. PMID 2687698.
Jefferis R, Lefranc MP (July–August 2009). «Human immunoglobulin allotypes: possible implications for immunogenicity». mAbs. 1 (4): 332–8. doi:10.4161/mabs.1.4.9122. PMC 2726606. PMID 20073133.
Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V (2009). «Preclinical development of monoclonal antibodies: considerations for the use of non-human primates». mAbs. 1 (5): 505–16. doi:10.4161/mabs.1.5.9676. PMC 2759500. PMID 20065651.
Vennepureddy A, Singh P, Rastogi R, Atallah JP, Terjanian T (June 2016). «Evolution of ramucirumab in the treatment of cancer - A review of literature». Journal of Oncology Pharmacy Practice. 23 (7): 525–539. doi:10.1177/1078155216655474. PMID 27306885.
de Zwart, Verena; Gouw, Samantha C; Meyer-Wentrup, Friederike AG (2016 թ․ հունվարի 19). «Antibody therapies for lymphoma in children». Cochrane Database of Systematic Reviews (1): CD011181. doi:10.1002/14651858.cd011181.pub2. ISSN 1465-1858. PMID 26784573.
Pul, Refik; Dodel, Richard; Stangel, Martin (March 2011). «Antibody-based therapy in Alzheimer's disease». Expert Opinion on Biological Therapy. 11 (3): 343–357. doi:10.1517/14712598.2011.552884. PMID 21261567.
van Dyck, Christopher (2017 թ․ օգոստոսի 24). «Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise». Biological Psychiatry. 83 (4): 311–319. doi:10.1016/j.biopsych.2017.08.010. PMC 5767539. PMID 28967385.
Panza, F.; Imbimbo, B. P.; Logroscino, G. (2014). «Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: The point of no return?». Expert Opinion on Biological Therapy. 14 (10): 1465–76. doi:10.1517/14712598.2014.935332. PMID 24981190.
Hanan, Eilat; Solomon, Beka (January 1996). «Inhibitory effect of monoclonal antibodies on Alzheimer's P-amyloid peptide aggregation». Amyloid. 2 (3): 130–133. doi:10.3109/13506129609014365.
Panza, F.; Imbimbo, B.P.; D'aOnofrio, G.; Pietrarossa, G.; Seripa, Davide; Frisardi, V. (November 2010). «Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease». V. 2 (6): 767–82. doi:10.2217/imt.10.80. PMID 21091109.
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH (September 2002). «A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours». British Journal of Cancer. 87 (6): 600–7. doi:10.1038/sj.bjc.6600517. PMC 2364249. PMID 12237768.
Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC (2000). «Emerging antibody-based HER2 (ErbB-2/neu) therapeutics». Breast Disease. 11: 113–24. doi:10.3233/bd-1999-11110. PMID 15687597.
Joyce JA, Fearon DT (April 2015). «T cell exclusion, immune privilege, and the tumor microenvironment». Science. 348 (6230): 74–80. Bibcode:2015Sci...348...74J. doi:10.1126/science.aaa6204. PMID 25838376.
Hooks MA, Wade CS, Millikan WJ (1991). «Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation». Pharmacotherapy. 11 (1): 26–37. doi:10.1002/j.1875-9114.1991.tb03595.x (inactive 2020 թ․ մայիսի 21). PMID 1902291.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2020 (link)
Chames P, Baty D (2009). «Bispecific antibodies for cancer therapy: the light at the end of the tunnel?». mAbs. 1 (6): 539–47. doi:10.4161/mabs.1.6.10015. PMC 2791310. PMID 20073127.
Linke, Rolf; Klein, Anke; Seimetz, Diane (2010). «Catumaxomab: Clinical development and future directions». mAbs. 2 (2): 129–136. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.
Scolnik PA (2009). «mAbs: a business perspective». mAbs. 1 (2): 179–84. doi:10.4161/mabs.1.2.7736. PMC 2725420. PMID 20061824.
Kelley B (2009). «Industrialization of mAb production technology: the bioprocessing industry at a crossroads». mAbs. 1 (5): 443–52. doi:10.4161/mabs.1.5.9448. PMC 2759494. PMID 20065641.

harvard.edu

ui.adsabs.harvard.edu

Sharma P, Allison JP (April 2015). «The future of immune checkpoint therapy». Science. 348 (6230): 56–61. Bibcode:2015Sci...348...56S. doi:10.1126/science.aaa8172. PMID 25838373.
Olinger GG, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L (October 2012). «Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques». Proceedings of the National Academy of Sciences of the United States of America. 109 (44): 18030–5. Bibcode:2012PNAS..10918030O. doi:10.1073/pnas.1213709109. PMC 3497800. PMID 23071322.
Köhler G, Milstein C (August 1975). «Continuous cultures of fused cells secreting antibody of predefined specificity». Nature. 256 (5517): 495–7. Bibcode:1975Natur.256..495K. doi:10.1038/256495a0. PMID 1172191.
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (May 1992). «Humanization of an anti-p185HER2 antibody for human cancer therapy». Proceedings of the National Academy of Sciences of the United States of America. 89 (10): 4285–9. Bibcode:1992PNAS...89.4285C. doi:10.1073/pnas.89.10.4285. PMC 49066. PMID 1350088.
Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR (1989). «Conformations of immunoglobulin hypervariable regions». Nature. 342 (6252): 877–83. Bibcode:1989Natur.342..877C. doi:10.1038/342877a0. PMID 2687698.
Joyce JA, Fearon DT (April 2015). «T cell exclusion, immune privilege, and the tumor microenvironment». Science. 348 (6230): 74–80. Bibcode:2015Sci...348...74J. doi:10.1126/science.aaa6204. PMID 25838376.

landesbioscience.com

Linke, Rolf; Klein, Anke; Seimetz, Diane (2010). «Catumaxomab: Clinical development and future directions». mAbs. 2 (2): 129–136. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.

nih.gov

pubmed.ncbi.nlm.nih.gov

Waldmann TA (March 2003). «Immunotherapy: past, present and future». Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576.
Sharma P, Allison JP (April 2015). «The future of immune checkpoint therapy». Science. 348 (6230): 56–61. Bibcode:2015Sci...348...56S. doi:10.1126/science.aaa8172. PMID 25838373.
Olinger GG, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L (October 2012). «Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques». Proceedings of the National Academy of Sciences of the United States of America. 109 (44): 18030–5. Bibcode:2012PNAS..10918030O. doi:10.1073/pnas.1213709109. PMC 3497800. PMID 23071322.
Baxter, David (December 2007). «Active and passive immunity, vaccine types, excipients and licensing». Occupational Medicine. 57 (8): 552–6. doi:10.1093/occmed/kqm110. PMID 18045976.
Modified from Carter P (November 2001). «Improving the efficacy of antibody-based cancer therapies». Nature Reviews. Cancer. 1 (2): 118–29. doi:10.1038/35101072. PMID 11905803.
Prof FC Breedveld (2000). «Therapeutic monoclonal antibodies». Lancet. 355 (9205): 735–740. doi:10.1016/S0140-6736(00)01034-5. PMID 10703815.
Köhler G, Milstein C (August 1975). «Continuous cultures of fused cells secreting antibody of predefined specificity». Nature. 256 (5517): 495–7. Bibcode:1975Natur.256..495K. doi:10.1038/256495a0. PMID 1172191.
Ritz J, Schlossman SF (January 1982). «Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma». Blood. 59 (1): 1–11. doi:10.1182/blood.V59.1.1.1. PMID 7032624.
Nadler LM, Stashenko P, Hardy R, Kaplan WD, Button LN, Kufe DW, Antman KH, Schlossman SF (September 1980). «Serotherapy of a patient with a monoclonal antibody directed against a human lymphoma-associated antigen». Cancer Research. 40 (9): 3147–54. PMID 7427932.
Stern M, Herrmann R (April 2005). «Overview of monoclonal antibodies in cancer therapy: present and promise». Critical Reviews in Oncology/Hematology. 54 (1): 11–29. doi:10.1016/j.critrevonc.2004.10.011. PMID 15780905.
Hudson PJ, Souriau C (January 2003). «Engineered antibodies». Nature Medicine. 9 (1): 129–34. doi:10.1038/nm0103-129. PMID 12514726.
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (May 1992). «Humanization of an anti-p185HER2 antibody for human cancer therapy». Proceedings of the National Academy of Sciences of the United States of America. 89 (10): 4285–9. Bibcode:1992PNAS...89.4285C. doi:10.1073/pnas.89.10.4285. PMC 49066. PMID 1350088.
Presta LG, Lahr SJ, Shields RL, Porter JP, Gorman CM, Fendly BM, Jardieu PM (September 1993). «Humanization of an antibody directed against IgE». Journal of Immunology. 151 (5): 2623–32. PMID 8360482.
Chothia C, Lesk AM, Tramontano A, Levitt M, Smith-Gill SJ, Air G, Sheriff S, Padlan EA, Davies D, Tulip WR (1989). «Conformations of immunoglobulin hypervariable regions». Nature. 342 (6252): 877–83. Bibcode:1989Natur.342..877C. doi:10.1038/342877a0. PMID 2687698.
Jefferis R, Lefranc MP (July–August 2009). «Human immunoglobulin allotypes: possible implications for immunogenicity». mAbs. 1 (4): 332–8. doi:10.4161/mabs.1.4.9122. PMC 2726606. PMID 20073133.
Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V (2009). «Preclinical development of monoclonal antibodies: considerations for the use of non-human primates». mAbs. 1 (5): 505–16. doi:10.4161/mabs.1.5.9676. PMC 2759500. PMID 20065651.
Vennepureddy A, Singh P, Rastogi R, Atallah JP, Terjanian T (June 2016). «Evolution of ramucirumab in the treatment of cancer - A review of literature». Journal of Oncology Pharmacy Practice. 23 (7): 525–539. doi:10.1177/1078155216655474. PMID 27306885.
de Zwart, Verena; Gouw, Samantha C; Meyer-Wentrup, Friederike AG (2016 թ․ հունվարի 19). «Antibody therapies for lymphoma in children». Cochrane Database of Systematic Reviews (1): CD011181. doi:10.1002/14651858.cd011181.pub2. ISSN 1465-1858. PMID 26784573.
Pul, Refik; Dodel, Richard; Stangel, Martin (March 2011). «Antibody-based therapy in Alzheimer's disease». Expert Opinion on Biological Therapy. 11 (3): 343–357. doi:10.1517/14712598.2011.552884. PMID 21261567.
van Dyck, Christopher (2017 թ․ օգոստոսի 24). «Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise». Biological Psychiatry. 83 (4): 311–319. doi:10.1016/j.biopsych.2017.08.010. PMC 5767539. PMID 28967385.
Panza, F.; Imbimbo, B. P.; Logroscino, G. (2014). «Amyloid-directed monoclonal antibodies for the treatment of Alzheimer's disease: The point of no return?». Expert Opinion on Biological Therapy. 14 (10): 1465–76. doi:10.1517/14712598.2014.935332. PMID 24981190.
Panza, F.; Imbimbo, B.P.; D'aOnofrio, G.; Pietrarossa, G.; Seripa, Davide; Frisardi, V. (November 2010). «Bapineuzumab: anti-β-amyloid monoclonal antibodies for the treatment of Alzheimer's disease». V. 2 (6): 767–82. doi:10.2217/imt.10.80. PMID 21091109.
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH (September 2002). «A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours». British Journal of Cancer. 87 (6): 600–7. doi:10.1038/sj.bjc.6600517. PMC 2364249. PMID 12237768.
Krauss WC, Park JW, Kirpotin DB, Hong K, Benz CC (2000). «Emerging antibody-based HER2 (ErbB-2/neu) therapeutics». Breast Disease. 11: 113–24. doi:10.3233/bd-1999-11110. PMID 15687597.
Joyce JA, Fearon DT (April 2015). «T cell exclusion, immune privilege, and the tumor microenvironment». Science. 348 (6230): 74–80. Bibcode:2015Sci...348...74J. doi:10.1126/science.aaa6204. PMID 25838376.
Hooks MA, Wade CS, Millikan WJ (1991). «Muromonab CD-3: a review of its pharmacology, pharmacokinetics, and clinical use in transplantation». Pharmacotherapy. 11 (1): 26–37. doi:10.1002/j.1875-9114.1991.tb03595.x (inactive 2020 թ․ մայիսի 21). PMID 1902291.{{cite journal}}: CS1 սպաս․ DOI inactive as of 2020 (link)
Chames P, Baty D (2009). «Bispecific antibodies for cancer therapy: the light at the end of the tunnel?». mAbs. 1 (6): 539–47. doi:10.4161/mabs.1.6.10015. PMC 2791310. PMID 20073127.
Linke, Rolf; Klein, Anke; Seimetz, Diane (2010). «Catumaxomab: Clinical development and future directions». mAbs. 2 (2): 129–136. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.
Scolnik PA (2009). «mAbs: a business perspective». mAbs. 1 (2): 179–84. doi:10.4161/mabs.1.2.7736. PMC 2725420. PMID 20061824.
Kelley B (2009). «Industrialization of mAb production technology: the bioprocessing industry at a crossroads». mAbs. 1 (5): 443–52. doi:10.4161/mabs.1.5.9448. PMC 2759494. PMID 20065641.

ncbi.nlm.nih.gov

Olinger GG, Pettitt J, Kim D, Working C, Bohorov O, Bratcher B, Hiatt E, Hume SD, Johnson AK, Morton J, Pauly M, Whaley KJ, Lear CM, Biggins JE, Scully C, Hensley L, Zeitlin L (October 2012). «Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques». Proceedings of the National Academy of Sciences of the United States of America. 109 (44): 18030–5. Bibcode:2012PNAS..10918030O. doi:10.1073/pnas.1213709109. PMC 3497800. PMID 23071322.
Janeway, Charles; Paul Travers; Mark Walport; Mark Shlomchik (2001). Immunobiology; Fifth Edition. New York and London: Garland Science. ISBN 978-0-8153-4101-7.
Carter P, Presta L, Gorman CM, Ridgway JB, Henner D, Wong WL, Rowland AM, Kotts C, Carver ME, Shepard HM (May 1992). «Humanization of an anti-p185HER2 antibody for human cancer therapy». Proceedings of the National Academy of Sciences of the United States of America. 89 (10): 4285–9. Bibcode:1992PNAS...89.4285C. doi:10.1073/pnas.89.10.4285. PMC 49066. PMID 1350088.
Jefferis R, Lefranc MP (July–August 2009). «Human immunoglobulin allotypes: possible implications for immunogenicity». mAbs. 1 (4): 332–8. doi:10.4161/mabs.1.4.9122. PMC 2726606. PMID 20073133.
Chapman K, Pullen N, Coney L, Dempster M, Andrews L, Bajramovic J, Baldrick P, Buckley L, Jacobs A, Hale G, Green C, Ragan I, Robinson V (2009). «Preclinical development of monoclonal antibodies: considerations for the use of non-human primates». mAbs. 1 (5): 505–16. doi:10.4161/mabs.1.5.9676. PMC 2759500. PMID 20065651.
van Dyck, Christopher (2017 թ․ օգոստոսի 24). «Anti-Amyloid-β Monoclonal Antibodies for Alzheimer's Disease: Pitfalls and Promise». Biological Psychiatry. 83 (4): 311–319. doi:10.1016/j.biopsych.2017.08.010. PMC 5767539. PMID 28967385.
Francis RJ, Sharma SK, Springer C, Green AJ, Hope-Stone LD, Sena L, Martin J, Adamson KL, Robbins A, Gumbrell L, O'Malley D, Tsiompanou E, Shahbakhti H, Webley S, Hochhauser D, Hilson AJ, Blakey D, Begent RH (September 2002). «A phase I trial of antibody directed enzyme prodrug therapy (ADEPT) in patients with advanced colorectal carcinoma or other CEA producing tumours». British Journal of Cancer. 87 (6): 600–7. doi:10.1038/sj.bjc.6600517. PMC 2364249. PMID 12237768.
Chames P, Baty D (2009). «Bispecific antibodies for cancer therapy: the light at the end of the tunnel?». mAbs. 1 (6): 539–47. doi:10.4161/mabs.1.6.10015. PMC 2791310. PMID 20073127.
Linke, Rolf; Klein, Anke; Seimetz, Diane (2010). «Catumaxomab: Clinical development and future directions». mAbs. 2 (2): 129–136. doi:10.4161/mabs.2.2.11221. PMC 2840231. PMID 20190561.
Scolnik PA (2009). «mAbs: a business perspective». mAbs. 1 (2): 179–84. doi:10.4161/mabs.1.2.7736. PMC 2725420. PMID 20061824.
Kelley B (2009). «Industrialization of mAb production technology: the bioprocessing industry at a crossroads». mAbs. 1 (5): 443–52. doi:10.4161/mabs.1.5.9448. PMC 2759494. PMID 20065641.

radiopaedia.org

Goel, Ayush. «Vasogenic cerebral oedema». radiopaedia.org (անգլերեն). Վերցված է 2017 թ․ նոյեմբերի 1-ին.

worldcat.org

de Zwart, Verena; Gouw, Samantha C; Meyer-Wentrup, Friederike AG (2016 թ․ հունվարի 19). «Antibody therapies for lymphoma in children». Cochrane Database of Systematic Reviews (1): CD011181. doi:10.1002/14651858.cd011181.pub2. ISSN 1465-1858. PMID 26784573.

zenodo.org

Waldmann TA (March 2003). «Immunotherapy: past, present and future». Nature Medicine. 9 (3): 269–77. doi:10.1038/nm0303-269. PMID 12612576.